Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1352957

registered interest
date	06/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what evidence his Department holds on the potential benefits of immunisation against covid-19 for people who have previously tested positive for that virus.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	43644
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>It is not known how long antibodies made in response to natural COVID-19 infection persist, and whether immunisation could offer more protection. However, it is expected the COVID-19 vaccine would boost any pre-existing antibodies from previous infection. There is no evidence of any safety concerns from vaccinating individuals with a history of COVID-19 infection or with detectable antibodies to COVID-19. Therefore, people who have had COVID-19 disease – whether confirmed or suspected – should still receive the COVID-19 vaccine.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 10/09/2021 09:12:09 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1342296

registered interest
date	30/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what data his Department holds on the effectiveness of the (a) Pfizer, (b) AstraZeneca and (c) Moderna covid-19 vaccinations at reducing transmission of covid-19.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	25123
answer	answer is ministerial correction date of answer 15/07/2021 answer text <p>Public Health England (PHE) publishes weekly COVID-19 vaccine surveillance reports which include the latest evidence on vaccine effectiveness against different outcomes. The following table shows the latest summary of evidence on vaccine effectiveness against different outcomes, including transmission, for Pfizer/BioNTech and University of Oxford/AstraZeneca as of 1 July.</p><p> </p><table><tbody><tr><td rowspan="3"><p>Outcome</p></td><td colspan="4"><p>Vaccine Effectiveness</p></td></tr><tr><td colspan="2"><p>Pfizer/BioNTech</p></td><td colspan="2"><p>Oxford/AstraZeneca</p></td></tr><tr><td><p>1 dose</p></td><td><p>2 doses</p></td><td><p>1 dose</p></td><td><p>2 doses</p></td></tr><tr><td><p>Symptomatic disease</p></td><td><p>55-70%*</p></td><td><p>85-95%*</p></td><td><p>55-70%*</p></td><td><p>70-85%**</p></td></tr><tr><td><p>Hospitalisation</p></td><td><p>75-85%*</p></td><td><p>90-99%**</p></td><td><p>75-85%*</p></td><td><p>80-99%***</p></td></tr><tr><td><p>Mortality</p></td><td><p>70-80%**</p></td><td><p>95-99%**</p></td><td><p>75-85%**</p></td><td><p>75-99%***</p></td></tr><tr><td><p>Infection</p></td><td><p>55-70%**</p></td><td><p>70-90%***</p></td><td><p>60-70%***</p></td><td><p>No data</p></td></tr><tr><td><p>Transmission (secondary cases)^</p></td><td><p>45-50%***</p></td><td><p>No data</p></td><td><p>35-50%***</p></td><td><p>No data</p></td></tr></tbody></table><p>Source: Table 3 <a href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fcovid-19-vaccine-surveillance-report&amp;data=04%7C01%7Ccovid19surv%40phe.gov.uk%7Cb2598e32058644d021bf08d916c0fea2%7Cee4e14994a354b2ead475f3cf9de8666%7C0%7C0%7C637565840415583246%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&amp;sdata=MFmH8qQxqsBUGSNXnO5e7tyCyPWBtYpuq%2FF3GUfu6AI%3D&amp;reserved=0" target="_blank">https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report</a></p><p> </p><p> </p><p>Notes:</p><ol><li>*High Confidence - Evidence from multiple studies which is consistent and comprehensive</li><li>**Medium Confidence - Evidence is emerging from a limited number of studies or with a moderately level of uncertainty</li><li>***Low Confidence - Little evidence is available at present and results are inconclusive</li><li>^effectiveness in reducing symptomatic secondary cases in households of a symptomatic index case</li></ol><p> </p><p>PHE plans to publish vaccine effectiveness data for Moderna when more evidence becomes available.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/07/2021 15:34:06 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1338211

registered interest
date	18/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to allow patients to choose which type of the covid-19 vaccination they receive.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	18560
answer	answer is ministerial correction date of answer 25/06/2021 answer text <p>There are no plans to do so.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 25/06/2021 11:34:02 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1337900

registered interest
date	17/06/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Life Sciences: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans he has to increase funding for (a) epilepsy treatments and medication and (b) UK life-sciences research more widely.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	17823
answer	answer is ministerial correction date of answer 22/06/2021 answer text <p>UK Research and Innovation (UKRI) funds research into epilepsy primarily through the Medical Research Council and the Biotechnology and Biological Sciences Research Council.</p><p>Funding for research projects that specifically refer to epilepsy in the project title or abstract in each of the last five years are set out in the table below. This does not include wider funding that contributes to epilepsy research.</p><p> </p><table><tbody><tr><td><p><strong>Financial year 2014/2015</strong></p></td><td><p><strong>Financial year 2015/2016</strong></p></td><td><p><strong>Financial year 2016/2017</strong></p></td><td><p><strong>Financial year 2017/2018</strong></p></td><td><p><strong>Financial year 2019/2020</strong></p></td></tr><tr><td><p>£8m</p></td><td><p>£6.2m</p></td><td><p>£8.4m</p></td><td><p>£9.7m</p></td><td><p>£10.6m</p></td></tr></tbody></table><p> </p><p>The DHSC-funded National Institute for Health Research (NIHR) facilitates and enables life science research, from early translational research, through clinical research, to applied health research. Life science companies can access NIHR resources at any stage in their clinical development process and DHSC ensures all parts of the NIHR are open to collaboration with industry.</p><p>The Government is committed to making the UK a global hub for life sciences. This means building on our strengths in basic science and medical research to ensure the UK remains at the forefront of worldwide efforts to tackle the most pressing healthcare challenges, from cancer to dementia.</p><p>As part of our commitment, the Government will raise total UK investment in R&amp;D to 2.4% of GDP by 2027. Life Sciences is critical to this – with the pharmaceutical industry accounting for one fifth of the total industrial spend on R&amp;D in the UK<sup>1</sup>.</p><p>We will also continue to support our fantastic research infrastructure, which bolsters the sector, stimulates economic growth and drives better outcomes for patients.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/06/2021 16:18:33 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1315259

registered interest
date	17/05/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what data his Department holds on the number of people who have had health complications after receiving a covid-19 vaccination.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	2418
answer	answer is ministerial correction date of answer 24/05/2021 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) operates the Yellow Card scheme on behalf of the Commission on Human Medicines (CHM). The scheme collects and monitors information on suspected safety concerns or incidents involving vaccines, medicines, medical devices, and e-cigarettes.</p><p>In the United Kingdom as of 5 May, 55,716 Yellow Cards have been reported for the Pfizer/BioNTech vaccine, 167,141 for University of Oxford/AstraZeneca, 1,081 for Moderna and 606 where the brand of the vaccine was not specified. For the Pfizer/BioNTech vaccine, University of Oxford/AstraZeneca, and Moderna vaccines the overall reporting rate is approximately three to six Yellow Cards per 1,000 doses administered.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 24/05/2021 15:37:48 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1314879

registered interest
date	14/05/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of legal protection for patients who have suffered from complications after receiving a covid-19 vaccination.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	1372
answer	answer is ministerial correction date of answer 02/06/2021 answer text <p>No specific assessment has been made.</p><p>Where individuals believe they have come to avoidable harm in relation to a vaccine, they could pursue a compensation claim against the producers of the vaccine.</p><p>While not constituting legal protection, the Vaccine Damage Payment Scheme (VDPS) was established in 1979, to help ease the burden on those individuals where, on very rare occasions, vaccination against certain diseases has caused severe disablement. COVID-19 was added to the scheme in 2020. The Scheme provides a one-off, tax-free, lump sum to those who are severely disabled as a result of a vaccination. The VDPS is not a compensation scheme and making a claim will not prevent someone from pursuing a compensation claim.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 02/06/2021 16:23:36 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1307143

registered interest
date	12/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to monitor the long-term effectiveness of covid-19 vaccination.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	178706
answer	answer is ministerial correction date of answer 19/04/2021 answer text <p>Public Health England is monitoring the effectiveness of the COVID-19 vaccines and has published early evidence on both the Pfizer/BioNTech and University of Oxford/AstraZeneca vaccines. This evidence suggests that a single dose of either vaccine is approximately 60 to 70% effective at preventing symptomatic disease in older adults and around 80% effective at preventing hospitalisations. There is also evidence that a single dose of the Pfizer/BioNTech vaccine is around 85% effective at preventing deaths.</p><p>As the COVID-19 vaccination programme continues in younger age groups, vaccine effectiveness estimates in these age groups will be published in due course. Vaccine effectiveness will continue to be monitored long-term in order to understand the need for booster doses.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 19/04/2021 16:20:30 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1304599

registered interest
date	22/03/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on whether there is a casual link between the Oxford AstraZeneca covid-19 vaccine and incidences of blood clots.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	173151
answer	answer is ministerial correction date of answer 29/03/2021 answer text <p>On 18 March 2021, the Medicines and Healthcare products Regulatory Agency, the United Kingdom regulator responsible for investigating medicines safety concerns, issued a statement setting out that the available evidence did not suggest that blood clots in veins are caused by the Oxford/AstraZeneca COVID-19 vaccine. This followed a rigorous scientific review of all the available data, including a detailed review of report cases as well as data from hospital admissions and general practitioner records. This has been confirmed by the Government’s independent advisory group, the Commission on Human Medicines, whose expert scientists and clinicians have also reviewed the available data.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 29/03/2021 15:33:49 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1304718

registered interest
date	22/03/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what support his Department is providing to people who do not have internet access at home to book a covid-19 vaccination appointment.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	173158
answer	answer is ministerial correction date of answer 29/03/2021 answer text <p>The National Booking Service is primarily sending physical invite letters to registered addresses. These letters give the option of booking online or by the free 119 phone line. Others can make an appointment on behalf of individuals who are not able to do so themselves. Follow up phone calls and letters are made to those who have been sent an initial letter but have not responded.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 29/03/2021 13:14:23 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy

1302226

registered interest
date	12/03/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential merits of adding Operating Department Practitioners (ODP) to the Patient Group Directions (PGD) to enable those with the relevant medical experience to play an active role in the covid-19 vaccination programme.
tabling member constituency	Kingston upon Hull West and Hessle
tabling member printed	Emma Hardy
uin	167940
answer	answer is ministerial correction date of answer 19/03/2021 answer text <p>Provisions have been made in The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020 to expand the workforce legally allowed to administer vaccines, including COVID-19 vaccinations. The changes enable more healthcare professionals, including Operating Department Practitioners, to participate in giving vaccinations with appropriate training and supervision. These regulations came into force on 16 October 2020.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 19/03/2021 16:30:31 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4645 label Biography information for Emma Hardy